NEWTON, Mass.--(BUSINESS WIRE)--May 30, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has finalized a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a single pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy.